Date: 2012-01-06
Type of information:
Compound: therapeutic antibodies to multiple oncology-related therapeutic targets.
Company: AnaptysBio (USA) Novartis (Switzerland)
Therapeutic area: Cancer Oncology
Type agreement: R&D
Action mechanism:
Disease: cancer
Details: AnaptysBio has announced the initiation of a second collaboration with Novartis.
This new alliance follows an initial partnership where AnaptysBio successfully delivered antibody candidates for Novartis’ development pipeline.
Under the terms of each alliance, AnaptysBio will utilize its proprietary SHM-XEL platform for the discovery and maturation of novel therapeutic antibodies to multiple oncology-related therapeutic targets.
Financial terms: Novartis will receive worldwide rights to develop and commercialize a limited number of antibodies against each therapeutic target generated by AnaptysBio. In addition to an upfront payment and resource-based compensation, AnaptysBio is eligible to receive milestone payments and royalties associated with the development and sale of any products derived from the alliance.
Latest news:
